Hims & Hers Health Faces Challenges In Legal Minefield Over Weight-Loss Drugs -- Market Talk

Dow Jones2025-06-30

0910 ET - A key question for Hims & Hers Health is whether it could continue to offer compounded treatments if a lawsuit is filed against it by Novo Nordisk, say Morgan Stanley analysts in a research note. Novo earlier this month abruptly ended its partnership with Hims & Hers after accusing it of illegally selling cheaper copycats of its Wegovy weight-loss drug and engaging in deceptive marketing. The analysts note that five of six defendants in lawsuits by Eli Lilly against compounders are continuing to offer compounded GLP-1s. Regardless, the analysts say a "a bear-case narrative for HIMS has resurfaced," and they expect these developments to be an overhang on the stock into Q2 earnings. Hims & Hers sold off 23% last week, but has more than doubled so far this year. (denny.jacob@wsj.com; @pennedbyden)

(END) Dow Jones Newswires

June 30, 2025 09:10 ET (13:10 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2547867092?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-30 21:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2547867092","market":"sg","top_or_hot":-1,"title":"Hims & Hers Health Faces Challenges In Legal Minefield Over Weight-Loss Drugs -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0910 ET - A key question for Hims &amp; Hers Health is whether it could continue to offer compounded treatments if a lawsuit is filed against it by Novo Nordisk, say <a href=\"https://laohu8.com/S/MSSXV\">Morgan Stanley</a> analysts in a research note. Novo earlier this month abruptly ended its partnership with Hims &amp; Hers after accusing it of illegally selling cheaper copycats of its Wegovy weight-loss drug and engaging in deceptive marketing. The analysts note that five of six defendants in lawsuits by Eli Lilly against compounders are continuing to offer compounded GLP-1s. Regardless, the analysts say a \"a bear-case narrative for HIMS has resurfaced,\" and they expect these developments to be an overhang on the stock into <a href=\"https://laohu8.com/S/QTWO\">Q2</a> earnings. Hims &amp; Hers sold off 23% last week, but has more than doubled so far this year. (denny.jacob@wsj.com; @pennedbyden) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 30, 2025 09:10 ET (13:10 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hims & Hers Health Faces Challenges In Legal Minefield Over Weight-Loss Drugs -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHims & Hers Health Faces Challenges In Legal Minefield Over Weight-Loss Drugs -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-06-30 21:10</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0910 ET - A key question for Hims &amp; Hers Health is whether it could continue to offer compounded treatments if a lawsuit is filed against it by Novo Nordisk, say <a href=\"https://laohu8.com/S/MSSXV\">Morgan Stanley</a> analysts in a research note. Novo earlier this month abruptly ended its partnership with Hims &amp; Hers after accusing it of illegally selling cheaper copycats of its Wegovy weight-loss drug and engaging in deceptive marketing. The analysts note that five of six defendants in lawsuits by Eli Lilly against compounders are continuing to offer compounded GLP-1s. Regardless, the analysts say a \"a bear-case narrative for HIMS has resurfaced,\" and they expect these developments to be an overhang on the stock into <a href=\"https://laohu8.com/S/QTWO\">Q2</a> earnings. Hims &amp; Hers sold off 23% last week, but has more than doubled so far this year. (denny.jacob@wsj.com; @pennedbyden) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 30, 2025 09:10 ET (13:10 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2133065610.SGD","symbol_name":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2547867092","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2547867092","pubTimestamp":1751289000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0910 ET - A key question for Hims & Hers Health is whether it could continue to offer compounded treatments if a lawsuit is filed against it by Novo Nordisk, say Morgan Stanley analysts in a research note. Novo earlier this month abruptly ended its partnership with Hims & Hers after accusing it of illegally selling cheaper copycats of its Wegovy weight-loss drug and engaging in deceptive marketing. The analysts note that five of six defendants in lawsuits by Eli Lilly against compounders are continuing to offer compounded GLP-1s. Regardless, the analysts say a \"a bear-case narrative for HIMS has resurfaced,\" and they expect these developments to be an overhang on the stock into Q2 earnings. Hims & Hers sold off 23% last week, but has more than doubled so far this year. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU0106831901.USD":"贝莱德世界金融基金A2","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","BK4516":"特朗普概念","HIMS":"Hims & Hers Health Inc.","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","BK4504":"桥水持仓","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","BK4588":"碎股","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","BK4196":"保健护理服务","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","BK4581":"高盛持仓","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU1548497426.USD":"安联环球人工智能AT Acc","LU0971096721.USD":"富达环球金融服务 A","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","BK4127":"投资银行业与经纪业"},"translate_title":"Hims&Hers Health在减肥药法律雷区面临挑战——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":0.9},"content_text":"0910 ET - A key question for Hims & Hers Health is whether it could continue to offer compounded treatments if a lawsuit is filed against it by Novo Nordisk, say Morgan Stanley analysts in a research note. Novo earlier this month abruptly ended its partnership with Hims & Hers after accusing it of illegally selling cheaper copycats of its Wegovy weight-loss drug and engaging in deceptive marketing. The analysts note that five of six defendants in lawsuits by Eli Lilly against compounders are continuing to offer compounded GLP-1s. Regardless, the analysts say a \"a bear-case narrative for HIMS has resurfaced,\" and they expect these developments to be an overhang on the stock into Q2 earnings. Hims & Hers sold off 23% last week, but has more than doubled so far this year. (denny.jacob@wsj.com; @pennedbyden) \n\n\n  (END) Dow Jones Newswires\n\n\n  June 30, 2025 09:10 ET (13:10 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2547867092","isCrawlerRequest":true}